Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Huang, Pengyu, Almeciga-Pinto, Ingrid, Jarpe, Matthew, van Duzer, John H, Mazitschek, Ralph, Yang, Min, Jones, Simon S, Quayle, Steven N
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356834/
https://ncbi.nlm.nih.gov/pubmed/27926524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13738
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky